🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: CC-220

Found 42 matching trials

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

PHASE1

This is a two-part study to be conducted at a single study site in the US. ...

Status

Completed

Location

PPD Development, LP

Start Date

2016-07

Trial ID

NCT02820935

Treatments Being Tested

CC-220 Rifampin Itraconazole

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

PHASE3

The purpose of the study is to determine the best treatment approach based ...

Status

Not Yet Recruiting

Location

Beth Israel Deaconess Medical Center (BIDMC)

Start Date

2026-06-08

Trial ID

NCT07624513

Treatments Being Tested

Isatuximab Iberdomide Bortezomib (B)Dexamethasone Melphalan Linvoseltamab On Body Delivery System (OBDS)

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

PHASE1

This is a multi-institution, open label, phase I/II study of Iberdomide, Ca...

Status

Suspended

Location

Lombardi Comprehensive Cancer Center

Start Date

2022-05-13

Trial ID

NCT05199311

Treatments Being Tested

Carfilzomib Iberdomide Oral Dexamethasone

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

PHASE1

This phase Ib trial tests the safety, side effects, and best dose of iberdo...

Status

Recruiting

Location

Mayo Clinic Hospital in Arizona

Start Date

2024-12-06

Trial ID

NCT06465316

Treatments Being Tested

Biospecimen Collection Bone Marrow Aspiration Bone Marrow Biopsy Computed Tomography Iberdomide Magnetic Resonance Imaging Positron Emission Tomography Teclistamab

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

PHASE1

This phase I/II trial studies the side effects and best dose of iberdomide ...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2026-10-28

Trial ID

NCT07437963

Treatments Being Tested

Bone Marrow Aspiration Bone Marrow Biopsy Computed Tomography Cyclophosphamide Dinutuximab Echocardiography Test FDG-Positron Emission Tomography Iberdomide Magnetic Resonance Imaging Multigated Acquisition Scan Nuclear Radiology Imaging Procedure Sargramostim Topotecan

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

PHASE1

This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 dif...

Status

Withdrawn

Location

Beth Israel Deaconess Medical Center

Start Date

2021-10-10

Trial ID

NCT04882163

Treatments Being Tested

CC-220 Polatuzumab vedotin Rituximab Tafasitamab Gemcitabine Cisplatin Dexamethasone Bendamustine Lenalidomide

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1

This phase I/II trial tests the safety, side effects, best dose, and effect...

Status

Recruiting

Location

Mary Greeley Medical Center

Start Date

2025-04-23

Trial ID

NCT06232044

Treatments Being Tested

Iberdomide Belantamab Mafodotin Dexamethasone Echocardiography Computed Tomography Magnetic Resonance Imaging Positron Emission Tomography Bone Marrow Biopsy Bone Marrow Aspiration Biospecimen Collection

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

PHASE1

This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as ...

Status

Terminated

Location

Local Institution - 106

Start Date

2020-11-11

Trial ID

NCT04464798

Treatments Being Tested

CC-220 Rituximab Obinutuzumab

A Phase 2 Study With CC-220 in Skin Sarcoidosis

PHASE2

This study will evaluate the safety, tolerability, pharmacokinetics and pre...

Status

Withdrawn

Location

Multiple Locations

Start Date

2014-11-01

Trial ID

NCT02192489

Treatments Being Tested

CC-220 0.3 mg Daily CC-220 0.6mg Daily Placebo

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

PHASE2

The purpose of this Phase 2, multicenter, randomized, placebo-controlled, d...

Status

Completed

Location

Clinical and Translational Research Center of Alabama, PC

Start Date

2017-08-31

Trial ID

NCT03161483

Treatments Being Tested

CC-220 Placebo

Previous Next